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Introduction {#sec005}
============

The use of quality indicators (QI) and contingent incentives aim to improve processes and outcomes in clinical practice. However, whether QI performance is modifiable by introducing a pay-for performance (P4P) scheme is still unclear \[[@pone.0232686.ref001]--[@pone.0232686.ref004]\]. Previous studies showed that P4P programs' effectiveness highly depend on type of health care system, investigated QI, study participants, patient population and the level of payment \[[@pone.0232686.ref002], [@pone.0232686.ref005], [@pone.0232686.ref006]\]. A systematic review \[[@pone.0232686.ref007]\] concluded that financial incentives targeting process and intermediate outcome indicators yield the highest effect, as they can be directly influenced by general practitioners (GP). In diabetes, which is one of the most common diseases for assessing quality of care, the most frequent process and intermediate outcome QIs are for glycated hemoglobin (HbA1c), blood pressure (BP) and serum cholesterol levels. From literature, we know that not only practice and GP, but also patient characteristics influence QI performance \[[@pone.0232686.ref008]--[@pone.0232686.ref012]\]. Case-mix adjustments are therefore often used to control for these mechanisms. However, the case-mix adjustments used and their effect on QI performance vary widely across studies \[[@pone.0232686.ref013]--[@pone.0232686.ref015]\].

In Switzerland, the use of QIs, especially in primary care, has been marginal. No P4P approach exists and no case-mix adjustments have been investigated \[[@pone.0232686.ref016]\]. Currently, a randomized controlled trial (RCT) testing the P4P approach in Swiss primary care using clinical routine data is ongoing \[[@pone.0232686.ref017]\]. The baseline data of this trial offer the opportunity to study the characteristics and QI performance of the study population and to analyze associations of practice, GP and patient covariates with QI performance.

Methods {#sec006}
=======

Study design and setting {#sec007}
------------------------

For this cross-sectional study we used baseline data collected within a cluster randomized controlled trial (trial registration number: ISRCTN13305645) \[[@pone.0232686.ref017]\]. Unit of cluster randomization was at practice level. The baseline assessment covered 12 months retrospectively ([Fig 1](#pone.0232686.g001){ref-type="fig"}). The trial was launched within the family medicine international classification of primary care (ICPC) research using electronic medical records (EMR) (FIRE) database of the Institute of Primary Care of the University of Zurich \[[@pone.0232686.ref018]\]. Up to June 2018, more than 400 GPs from the German-speaking area of Switzerland participated in the FIRE project. The participants contribute anonymized data containing the following components: administrative information, vital signs, laboratory values, medication data and diagnostic codes coded according to ICPC-2 \[[@pone.0232686.ref019]\]. Up to June 2018, information from more than 500,000 patients and 5 million consultations are available. Further, at individual project entry the participating GPs manually provided additional information concerning structural details to the study nurse of the research team. According to the local ethics committee of the canton of Zurich, the project does not fall under the scope of the law on human research and therefore no ethical consent was necessary (BASEC-Nr. Req-2017-00797).

![Flowchart.\
Study design including inclusion/exclusion criteria, FIRE = Family medicine ICPC research using electronic medical records; GP = General practitioner.](pone.0232686.g001){#pone.0232686.g001}

Participants {#sec008}
------------

For the trial, the following data availability and data quality criteria had to be fulfilled on GP level: a) continuous data delivery since January 2017, b) delivering HbA1c and BP values in more than 10% of their patients with diabetes, and c) consulting a minimum of five patients with diabetes. In June 2018, the eligible GPs received an invitation to participate in the study. Per practice, multiple GPs were contacted if data availability and data quality criteria were fulfilled ([Fig 1](#pone.0232686.g001){ref-type="fig"}). From the participating GPs, all patients diagnosed with diabetes at least 4 months before the baseline date were subsequently identified according to at least one of the following criteria:

1.  Patients with ICPC-2 codes T89 (insulin dependent diabetes mellitus) and T90 (insulin independent diabetes mellitus)

2.  Patients with antidiabetic medication (oral antidiabetics and/or insulin) according to the anatomical therapeutic chemical (ATC) classification system (A10A, A10B, A10X) \[[@pone.0232686.ref020]\]

Database query and variables {#sec009}
----------------------------

From the included GPs, we retrieved demographic (year of birth, gender) and work setting related data (practice location to assess urbanity \[[@pone.0232686.ref021]\], practice type (single or group practice), physician's network participation). From the included patients we retrieved following data: a) demographics (year of birth, gender), b) laboratory values(HbA1c, cholesterol) and vital signs (BP, body mass index (BMI) recorded within the observation period, c) prescription of relevant medication (insulin, oral anti-diabetic medication, anti-hypertensive medication, anti-thrombotic medication, lipid lowering medication) recorded within the observation period, d) presence of comorbidities relevant for diabetes (obesity, arterial hypertension, hyperlipidemia, microvascular complications (chronic kidney disease stage 3a or higher, peripheral vascular disease, retinopathy or neuropathy) and macrovascular complications (coronary heart disease (CHD), chronic heart failure (CHF), stroke) available in the full patient history in the FIRE database. Detailed information about the identification scheme for comorbidities is depicted in the [S1 Table](#pone.0232686.s001){ref-type="supplementary-material"}. For each patient, we determined the baseline performance (fulfilled/not fulfilled) based on the QI defined in the P4P trial \[[@pone.0232686.ref022], [@pone.0232686.ref023]\]. QIs are listed in [Table 1](#pone.0232686.t001){ref-type="table"}. Furthermore, we calculated the cumulative QI performance, which is the number of fulfilled QIs per patient.

10.1371/journal.pone.0232686.t001

###### Quality indicators used to assess performance.

![](pone.0232686.t001){#pone.0232686.t001g}

                   Process indicators                                                                                                Outcome indicators
  ---------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  Blood pressure   Proportion of patients with diabetes with at least one blood pressure measure-meant in the preceding 12 months.   Proportion of patients with diabetes with a blood pressure measurement \< 140/85 mmHg in the preceding 12 months.
  HbA1c            Proportion of patients with diabetes with at least one measurement of HbA1c in the preceding 12 months.           Proportion of patients with diabetes with HbA1c levels \< 7.5% in the preceding 12 months.
  Cholesterol      Proportion of patients with diabetes with at least one cholesterol measurement in the preceding 12 months.        Proportion of patients with diabetes with total cholesterol \< 5 mmol/l in the preceding 12 months.

HbA1c = measure for glycated hemoglobin;

Objectives {#sec010}
----------

Objectives of the current study are:

-   Description of the study population characteristics, including baseline QI performance

-   Examination of the associations of practice, GP and patient covariates with QI performance

Statistical analysis {#sec011}
--------------------

We presented categorical data as frequencies and percentages, continuous variables as means and standard deviations (SD) or median and interquartile range (IQR), as appropriate. Overall QI performances are expressed as percentage of patients meeting the indicator (numerator), in reference to all eligible patients (denominator). We used hierarchical multivariable logistic regression models, with the practice and the GP nested within practices as random variables, to examine the independent association of each QI performance on patient level with practice (practice location, practice type), GP (age, sex, physician's network participation) and patient characteristics (age, sex, number of comorbidities, number of consultations, number of consulted GPs). Number of medications and BMI were not considered as covariates for the regression model, since they were used to identify certain comorbidities. We ran the model for each of the six QIs. The same model variables were used in a hierarchical multivariable binomial logistic regression model to assess the association for the cumulative QI performance, whereas the dependent variable was defined as the cumulative QI performance. We reported odds ratios (OR) and 95% confidence intervals (CI) for each factor included in the model and used random effects to study variance on practice and GP level. All analyses were performed using the statistical software R (version 3.5.0) \[[@pone.0232686.ref024]\].

Results {#sec012}
=======

Sample characteristics {#sec013}
----------------------

We included 71 GPs from 43 practices in the study. We enrolled 61 GPs in cohort 1, starting in July 2018, whereas 10 GPs were enrolled in a second cohort, starting in September 2018. Their mean age was 52 years (SD 9.3), 72% were male and 92% worked in a group practice. They practiced in 83% in an urban setting and 93% were member of a physician's network. With the participating GPs, a total of 3,833 patients with diabetes were included. The median number of patients with diabetes per GP was 44 (IQR: 28--79), corresponding to 5% (IQR: 3% - 7%) of GP's patient list size. These patients were 57% male and had a mean age of 68.3 years (SD 13.4). The first record of diabetes within the database was on average 2.6 years (IQR: 1.3--6.2) before baseline assessment.

93.8% of patients had at least one, 37.9% three or more comorbidities. The most frequent comorbidity was arterial hypertension, followed by hyperlipidemia and obesity (see [Table 2](#pone.0232686.t002){ref-type="table"} for exact numbers on comorbidities). Diabetes-associated microvascular complications were identified in 18.3% of patients, macrovascular complications in 10.0% (see [Table 2](#pone.0232686.t002){ref-type="table"} for exact numbers).

10.1371/journal.pone.0232686.t002

###### Patient, treatment and disease characteristics.

![](pone.0232686.t002){#pone.0232686.t002g}

                                                     Median, mean or n   IQR, SD or %
  -------------------------------------------------- ------------------- --------------
  **Patient characteristics**                                            
  Male gender                                        2198                57.3
  Age at baseline (years)                            68.3                13.4
  First record of diabetes before baseline (years)   2.6                 1.3--6.2
  **Diabetes associated Comorbidities**                                  
  Arterial hypertension                              3322                86.7
  Hyperlipidemia                                     2262                59.0
  Obesity                                            1589                41.5
  Chronic kidney disease                             454                 11.8
  Peripheral vascular disease                        134                 3.5
  Neuropathy                                         100                 2.6
  Retinopathy                                        14                  0.4
  Coronary heart disease                             234                 6.1
  Heart failure                                      83                  2.2
  Stroke                                             67                  1.7
  **Treatment and disease characteristics**                              
  Number of consultations                            8                   5--15
  Number of BP measurements                          2.3                 2.6
  Number of HbA1c measurements                       2.1                 1.5
  Number of cholesterol measurements                 0.7                 0.9
  Number of BMI measurements                         1.2                 1.6
  Systolic BP value (mmHg)                           135.9               126.5--146.1
  Diastolic BP value (mmHg)                          80                  73.7--85.0
  HbA1c value (%)                                    6.8                 6.3--7.5
  Cholesterol value (mmol/l)                         4.5                 3.8--5.4
  BMI value (kg/m2)                                  29.53               26.3--33.3
  **Diabetes associated medication**                                     
  Oral anti-diabetic medication                      1978                51.6
  Insulin                                            278                 7.5
  Combination of oral medication and insulin         520                 13.6
  Antihypertensive medication                        1837                47.9
  Antiplatelet therapy and anticoagulants            1542                40.2
  Lipid lowering medication                          1359                35.5

IQR = interquartile range; SD = standard deviation; BP = blood pressure; HbA1c = measure for glycated hemoglobin; BMI = body mass index;

Treatment and disease characteristics {#sec014}
-------------------------------------

On average, patients had eight consultations (IQR: 5--15) at the GPs' practice in the 12 months preceding baseline. In those consultations, average numbers of BP measurements, HbA1c testing, cholesterol testing and BMI measurements, as well as the parametric values thereof are reported in [Table 2](#pone.0232686.t002){ref-type="table"}. Regarding anti-diabetic therapy, we found that 72.7% of patients received a therapy; most often oral medication only, followed by the combination of an oral and an insulin therapy and insulin only (see [Table 2](#pone.0232686.t002){ref-type="table"} for the exact numbers). Moreover, 47.9% of patients received an antihypertensive agent, 40.2% antiplatelet therapy and anticoagulants, and 35.5% lipid-lowering therapy. For proportions of patients achieving the defined QIs see [Table 3](#pone.0232686.t003){ref-type="table"}. On average, patients fulfilled 3.6 (SD: 1.9) QIs, whereas 17.2% of the patients fulfilled all QIs.

10.1371/journal.pone.0232686.t003

###### Proportion of patients achieving the defined quality indicators.

![](pone.0232686.t003){#pone.0232686.t003g}

  Description                                                                                                         Quality indicator performance % (n)
  ------------------------------------------------------------------------------------------------------------------- -------------------------------------
  Proportion of patients with diabetes with at least one blood pressure measurement in the preceding 12 months.       75.6 (2,899)
  Proportion of patients with diabetes with a blood pressure measurement \< 140/85 mmHg in the preceding 12 months.   50.6 (1,941)
  Proportion of patients with diabetes with at least one measurement of HbA1c in the preceding 12 months.             80.4 (3,082)
  Proportion of patients with diabetes with HbA1c levels \< 7.5% in the preceding 12 months.                          66.3 (2,543)
  Proportion of patients with diabetes with at least one cholesterol measurement in the preceding 12 months.          49.3 (1,891)
  Proportion of patients with diabetes with total cholesterol \< 5 mmol/l in the preceding 12 months.                 33.5 (1,285)

HbA1c = measure for glycated hemoglobin;

Associations with QI performance {#sec015}
--------------------------------

The regression model revealed the following results: for practice and GP characteristics, we did not find evidence of significant associations with QI performance ([Table 4](#pone.0232686.t004){ref-type="table"}), except for female GPs measuring BP more often (OR 1.75 95% CI 1.03--2.98) and older GPs achieving BP target level in a larger share of their patients (OR 1.23 95% CI 1.02--1.49). On patient level, age had no influence on achieving BP QIs (process indicator: OR 1.06 95% CI 0.99--1.13, outcome indicator: OR 1.00 95% CI 0.95--1.06). Higher age was significantly associated with achieving the HbA1c QIs more often (process indicator: OR 1.07 95% CI 1.01--1.14, outcome indicator: OR 1.10 95% CI 1.04--1.16), but with achieving the cholesterol QIs less often (process indicator: OR 0.86 95% CI 0.81--0.91, outcome indicator: OR 0.92 95% CI 0.86--0.97). Female gender was also significantly associated with achieving the cholesterol QIs more often (process indicator: OR 0.73 95% CI 0.63--0.85, outcome indicator: OR 0.5 95% CI 0.42--0.58). For patients with an increasing number of diabetes-relevant comorbidities, the QIs were more often fulfilled (see [Table 4](#pone.0232686.t004){ref-type="table"} for OR & 95% CI), whereas the number of consultations only had a positive effect on fulfilling the BP and HbA1c QIs ([Table 4](#pone.0232686.t004){ref-type="table"}). With an increasing number of GPs providing care for the same diabetes patient, the chances in achieving process indicators decreased ([Table 4](#pone.0232686.t004){ref-type="table"}). Number of years since diabetes diagnosis was significantly associated with achieving HbA1c outcome QI less often (OR 0.96 95% CI 0.93--0.99), but achieving cholesterol outcome QI more often (OR 1.08 95% CI 1.04--1.12). Associations of the cumulative QIs are presented in [Fig 2](#pone.0232686.g002){ref-type="fig"}.

![Associations with cumulative quality indicator performances.\
ref = reference; GP = General practitioner.](pone.0232686.g002){#pone.0232686.g002}

10.1371/journal.pone.0232686.t004

###### Results of hierarchical multivariable regression analysis of quality indicator performance.
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                                         OR                  95% CI              P-value   OR     95% CI       P-value
  -------------------------------------- ------------------- ------------------- --------- ------ ------------ ---------
                                         Blood pressure                                                        
                                         Process indicator   Outcome indicator                                 
  Practice type (ref = group practice)   2.07                0.86--4.97          0.10      1.41   0.75--2.64   0.29
  Practice location (ref = urban)        0.90                0.47--1.74          0.76      0.83   0.51--1.35   0.45
  Network participation (ref = yes)      0.74                0.30--1.84          0.52      1.09   0.55--2.17   0.81
  GP gender (ref = male)                 1.75                1.03--2.98          \<0.05    1.38   0.93--2.05   0.11
  GP age (per 10 years)                  1.11                0.86--1.43          0.43      1.23   1.02--1.49   \<0.05
  Patient gender (ref = male)            0.90                0.76--1.07          0.25      1.00   0.87--1.15   0.98
  Patient age (per 10 years)             1.06                0.99--1.13          0.09      1.00   0.95--1.06   0.93
  Number of GPs                          0.89                0.82--0.96          \<0.01    0.98   0.92--1.05   0.58
  Number of consultations                1.05                1.04--1.07          \<0.001   1.06   1.05--1.07   \<0.001
  Number of comorbidities                1.76                1.61--1.93          \<0.001   1.15   1.07--1.23   \<0.001
  Number of years since diagnosis        0.98                0.94--1.01          0.21      1.02   0.98--1.05   0.32
                                         HbA1c                                                                 
                                         Process indicator   Outcome indicator                                 
  Practice type (ref = group practice)   0.71                0.39--1.31          0.28      0.75   0.46--1.24   0.26
  Practice location (ref = urban)        0.75                0.45--1.23          0.26      1.05   0.71--1.56   0.81
  Network participation (ref = yes)      0.94                0.48--1.82          0.85      0.78   0.45--1.35   0.38
  GP gender (ref = male)                 1.39                0.94--2.05          0.10      1.32   0.93--1.87   0.12
  GP age (per 10 years)                  0.90                0.74--1.08          0.24      0.95   0.81--1.11   0.51
  Patient gender (ref = male)            0.85                0.72--1.02          0.08      0.91   0.79--1.05   0.19
  Patient age (per 10 years)             1.07                1.01--1.14          \<0.05    1.10   1.04--1.16   \<0.001
  Number of GPs                          0.89                0.82--0.97          \<0.01    0.96   0.90--1.03   0.25
  Number of consultations                1.05                1.04--1.07          \<0.001   1.02   1.01--1.03   \<0.001
  Number of comorbidities                1.83                1.66--2.01          \<0.001   1.48   1.38--1.60   \<0.001
  Number of years since diagnosis        0.99                0.95--1.03          0.66      0.96   0.93--0.99   \<0.01
                                         Cholesterol                                                           
                                         Process indicator   Outcome indicator                                 
  Practice type (ref = group practice)   1.17                0.54--2.56          0.69      1.01   0.47--2.17   0.98
  Practice location (ref = urban)        0.96                0.50--1.84          0.90      1.24   0.65--2.35   0.51
  Network participation (ref = yes)      0.59                0.25--1.41          0.24      0.60   0.26--1.41   0.25
  GP gender (ref = male)                 1.14                0.75--1.74          0.54      1.20   0.82--1.76   0.34
  GP age (per 10 years)                  0.81                0.66--1.01          0.06      0.86   0.71--1.04   0.12
  Patient gender (ref = male)            0.73                0.63--0.85          \<0.001   0.50   0.42--0.58   \<0.001
  Patient age (per 10 years)             0.86                0.81--0.91          \<0.001   0.92   0.86--0.97   \<0.01
  Number of GPs                          0.89                0.83--0.95          \<0.001   0.92   0.85--0.98   \<0.05
  Number of consultations                1.00                0.99--1.00          0.27      1.01   1.00--1.01   0.12
  Number of comorbidities                1.89                1.75--2.04          \<0.001   1.40   1.30--1.51   \<0.001
  Number of years since diagnosis        1.02                0.99--1.06          0.18      1.08   1.04--1.12   \<0.001

OR = Odds ratio; CI = confidence interval; ref = reference; GP = general practitioner.

Hierarchical random effects for GPs nested in practices showed, that the variation on practice and GP level are considerable but different for each QI (see [S1](#pone.0232686.s002){ref-type="supplementary-material"}--[S6](#pone.0232686.s007){ref-type="supplementary-material"} Figs). For the model with the cumulative QI, only little variation was associated with the practice level and the unexplained variation was associated with the GP level (see [S7 Fig](#pone.0232686.s008){ref-type="supplementary-material"}).

Discussion {#sec016}
==========

In this study, we explored associations of practice, GP and patient characteristics with QI performance. We found no substantial effect from GP and practice characteristics on QI performance, whereas several patient characteristics had a small effect.

The patient population included in our study is highly comparable to the patient population of a recent RCT and a cross-sectional study in Swiss primary care \[[@pone.0232686.ref025], [@pone.0232686.ref026]\] in terms of age, gender, comorbidities and consultation count. In terms of age and gender, our study population was also highly comparable to other European diabetes populations, whereas in terms of comorbidities our population had less micro- and macro-vascular diseases \[[@pone.0232686.ref027]\]. Number of years since diabetes diagnosis was much shorter in our study, which is explained by the fact limited data were available from before GPs participated in the FIRE project.

Comparing QI performances from our study with previous studies is fairly challenging, due to heterogeneity regarding study type, patient population, clinical thresholds and underlying financial incentives of different health care systems \[[@pone.0232686.ref013], [@pone.0232686.ref027], [@pone.0232686.ref028]\]. The proportions of patients fulfilling the process and outcome indicators for BP and HbA1c were highly comparable to the methodological similar study of van Doorn-Klomberg et al. 2015 \[[@pone.0232686.ref013]\], whereas the European cross-sectional study of Stone et al. 2013 \[[@pone.0232686.ref027]\] reported process indicators above 90%. A recent Swiss study based on insurance claims data found slightly higher annual rates for HbA1c and total cholesterol measurements \[[@pone.0232686.ref029]\]. When comparing to the Swiss quality and outcome feasibility study of Djalali et al. 2014, which based on the same EMR database, an improvement for each QI was achieved \[[@pone.0232686.ref016]\]. However, QI performance in our study still showed room for improvement, especially for outcome indicators. Possible reasons for such poor performances might be clinical inertia to intensify treatment, poor patient adherence, or failure in structural data capturing \[[@pone.0232686.ref016], [@pone.0232686.ref030], [@pone.0232686.ref031]\].

Regression analysis revealed that included characteristics had no or very little effect on process and outcome indicators. Most significant effects were found on patient level, and the greatest positive effect on QI performance was an increasing number of diabetes-relevant comorbidities. More intensive consultations or an increased awareness and risk factor management in multimorbid patients with certain comorbidities might explain this finding \[[@pone.0232686.ref032], [@pone.0232686.ref033]\]. However, the finding is contradictory to the guidelines of the American Diabetes Association, recommending a more lenient therapy in multimorbid patients \[[@pone.0232686.ref034]\]. The same is recommended for disease duration, which we could confirm being associated with lower rates of target value performances for HbA1c. Also notifiable are gender differences regarding QI performance. Female patients had significantly fewer cholesterol measurements and if measured, a higher level. This is highly congruent to recent results investigating gender disparities in diabetes care and revealing gender disparities in risk factor management, prescribing behavior and guideline adherence \[[@pone.0232686.ref035], [@pone.0232686.ref036]\].

Number of consultations was positively associated with QI performance. Van Doorn-Klomberg interpreted similar results in their study as a measure of patients' adherence to a treatment plan, based on an automatic invitation for 3-monthly consultations \[[@pone.0232686.ref013]\]. In Switzerland, the study of Frei et al. 2013 also found no association with consultation count, which might be due to the fact that in Switzerland a structured invitation mechanism for follow-up appointments is uncommon. Another known factor associated with increased quality of diabetes care is continuity of care \[[@pone.0232686.ref037], [@pone.0232686.ref038]\]. We did not explicitly measure continuity of care, but we found a negative association between number of treating GPs and all three process indicators, and a negative association with the outcome indicator of cholesterol. This finding is not completely in line with Lustman et al. 2016 \[[@pone.0232686.ref037]\], reporting a positive effect of continuity of care on the major clinical outcomes. Furthermore, we know from literature, that several other patient factors, such as ethnicity/culture, financial resources, beliefs, knowledge and other person-related characteristics, influence diabetes care \[[@pone.0232686.ref012], [@pone.0232686.ref039]\]. Unfortunately, information on these characteristics were not available within the study setting.

In our study, female GPs had a small but positive effect on QI performance, which is repeatedly observed \[[@pone.0232686.ref008], [@pone.0232686.ref014]\]. However, our model also revealed that variation exists between practices and GPs, which cannot be explained by our model. This might be due to a lack of important information about practice and GP characteristics, such as practice culture, working style and accessibility of disease management tools \[[@pone.0232686.ref010], [@pone.0232686.ref012], [@pone.0232686.ref040]\]. Overall, it is in line with previous research, that organization, GP and patient characteristics can only explain small proportions of variation in diabetes care \[[@pone.0232686.ref010], [@pone.0232686.ref011]\].

Strengths and limitations of this study {#sec017}
---------------------------------------

A major strength of our study is the relevance of the disease under study: Diabetes is highly prevalent and associated with high morbidity, mortality and costs \[[@pone.0232686.ref041]\]. Furthermore, we did not allow for exclusion of individual patients and included the entire spectrum of patients with diabetes, reflecting the everyday situation of a GP. We were therefore able to show high generalizability of our data. Another major strength of our study is the wide GP coverage of the FIRE database. FIRE is to date the only database of clinical routine data in Swiss primary care and covers about 10% of GPs practicing in the German-speaking area of Switzerland \[[@pone.0232686.ref042]\]. GPs participating in the P4P trial are representative for the Swiss GPs in terms of age, but are more often male than the average Swiss GP. However, GPs participating in the FIRE project and additionally in the P4P trial might not be completely representative, as those voluntarily participating in research projects are highly motivated and better performing \[[@pone.0232686.ref043]\].

This study faces methodological drawbacks commonly present in EMR database studies, i.e. the cross-sectional design, data structure and potential missing data. Not all diabetes-specific comorbidities can be depicted in the FIRE database, due to data structure in the EMR, which does not allow for structural recording of several factors, such as lifestyle, hereditary factors, severity and duration. Duration of diabetes was approximated by using the first record as the onset of diabetes. However, this might highly underestimate the duration, as we have no information from the patient before the GP participated in the FIRE project. Furthermore, information about socioeconomic status and other person- related characteristics are not recorded in the EMR. Missing data is the largest source of bias for our study, as we cannot distinguish between real missing data (not measured) and technical missing data (not available for FIRE due to data capturing or transmission problems for example). This issue is of major concern for the QI measures and comorbidity identification, where we assumed that if there was no positive record, no measurement or disease was present. The proportions not fulfilling the process indicators disclose the maximal percentage of missing data for QI measures. We tried to minimize the amount of missing data by setting a minimum standard of data availability for each GP to be contacted for recruitment. Further limitations of our study are that a few patients were not diagnosed with diabetes over the entire observation period, as the identification needed to be present four months prior to baseline. In addition, type 1 and type 2 patients cannot be fully distinguished due to data structure. However, from the prescription of medications one can conclude that the majority of patients included were patients with type 2 diabetes.

Conclusion {#sec018}
==========

The influence of practice, GP and patient characteristics on QI performance was surprisingly small and room for improvement in QI performance of Swiss GPs seems to exist in diabetes care. We believe that improving the quality of QI measurements is an important step towards correctly assessing quality of care in primary care. In order to achieve a valid assessment of quality of care, it is essential to comprehensively include all potentially meaningful provider and patient characteristics within routine data collection. Moreover, it will be of particular interest to see whether the P4P approach leads to higher QI performance.

Supporting information {#sec019}
======================

###### Identification scheme for comorbidities and co-medication.

BMI = Body mass index, ICPC = International classification of primary care, ATC = anatomical therapeutic chemical code, LDL = low density lipoprotein, HDL = High density lipoprotein, GFR = glomerular filtration rate.

(DOCX)

###### 

Click here for additional data file.

###### Log OR representing variation from hierarchical multivariable regression analysis for blood pressure process indicator.

GP = general practitioner.
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Click here for additional data file.

###### Log OR representing variation from hierarchical multivariable regression analysis for blood pressure outcome indicator.

GP = general practitioner.
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Click here for additional data file.

###### Log OR representing variation from hierarchical multivariable regression analysis for HbA1c process indicator.

GP = general practitioner.
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Click here for additional data file.

###### Log OR representing variation from hierarchical multivariable regression analysis for HbA1c outcome indicator.

GP = general practitioner.
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Click here for additional data file.

###### Log OR representing variation hierarchical multivariable regression analysis for cholesterol process indicator.

GP = general practitioner.
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Click here for additional data file.

###### Log OR representing variation from hierarchical multivariable regression analysis for cholesterol outcome indicator.

GP = general practitioner.
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Click here for additional data file.

###### Log OR representing variation from hierarchical multivariable regression analysis for cumulative quality indicator.

GP = general practitioner.
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Click here for additional data file.
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Quality performance and associated factors in Swiss diabetes care -- a cross-sectional study

PLOS ONE

Dear Ms Meier,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Feb 20 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Valérie Pittet, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please ensure you have included the registration number for the clinical trial referenced in the manuscript.

3\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Reviewer \#1: Here is a list of specific comments. Note: line and page numbering in reviews and comments is based on ruler applied in Editorial Manager-generated PDF.

1\. Page 3, line 68: What was the unit of cluster randomization?

2\. Page 3, lines 74--75: What was the difference between the 660000 patients mentioned in this sentence and the 3,833 patients in Figure 1?

3\. Page 4, lines 87--88: Please include the definition of "baseline date".

4\. Page 4, lines 96--102: What was the timing of the retrospectively retrieved patients' data? How was the timing relative to the timing of baseline?

5\. Page 5, lines 114--116:

(5a) The use of "population" was not clear. What was the unit (e.g., practice, GP, etc.) that the QI performance was defined?

(5b) The term "indicator" (or more specifically, QI) was not defined previously.

6\. Page 5, line 117:

(6a) To this point, the level of practice was not defined clearly. Was the practice selected first and then GP?

(6b) Please define practice type.

7\. Page 5, line 118:

(7a) Did "each QI" mean 'each QI performance'? Please make it clear.

(7b) Did the model include each QI performance as a binary outcome? Please make it clear.

8\. Page 5, lines 121--122: Please define the cumulative QI performance clearly.

9\. Page 5, line 127: 'Sample' would be a better term than "population".

10\. Page 5, line 132: What did "the patient population" refer to?

11\. Page 6, Table 1: Please comment on 'the diabetic status was defined 4 months prior to baseline but QI's were defined 12 months prior to baseline'. Some patients may not be diabetic when QI's were collected.

12\. Page 7, line 157: Throughout this section, I suggest to write non-significant associations as 'not find evidence of significant associations'.

13\. Page 7, lines 173--174: Please provide more details about variations on practice and on GP level in the Methods section.

14\. Page 7, Table 2: Please define the "process" and "outcome" indicators in the Methods section.

Reviewer \#2: Please note that I have uploaded my comments as an attachment in order to retain formatting. This should make it easier for the authors to see any edits made to sentences containing typographical errors.

Reviewer \#3: 1. The aim of this study was to describe QI performance levels and to analyze associations of QI performance with practice, GP and patient covariates. The authors are to be commended that their research is timely. Diabetes prevalence is rising and the condition increases the risk of morbidity and mortality.

2\. It might strengthen the manuscript if the Introduction section were rewritten to link the P4P approach better to the methods and results section and the variables measured and analysed in the current study. It is not clear how financial incentives were taken into account in the Result and Discussion sections.

3\. Design and methods. Data regarding participating GPs and the care of their patients are appropriate in relation to the aim of this study. Nevertheless, the GP's are a rather selected group compared to the total population of GP's in primary care. The authors may consider to further illuminate potential bias related to selection of participants. As to patient data, there is a lack of information related to clinical variables, ex. diabetes type etc.

4\. Results. The data support the conclusion. However, the interpretation of the results should be discussed with more caution. Limitations of the study are not sufficiently outlined.

5\. The discussion section is interesting. However, a wider perspective in the discussion section might benefit the manuscript. If the literature references could include more studies from other countries in addition to Swiss primary care, it might be a more interesting paper also for international readers.

6.In conclusion, this is an interesting and timely manuscript. More effort might however, be put in further clarification about the sample population, and how selection bias might have affected the results.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: Reviewer comments - PONE-D-19-32658 .pdf

###### 

Click here for additional data file.
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28 Feb 2020

Dear Dr. Pittet,

Thank you for considering our manuscript.

We were very glad to receive the reviewers' thoughtful and constructive comments. These allowed us to substantially improve the manuscript and to further elaborate its content. Please find the point-by-point response table attached as well as a tracked-changes version and a clean version of the revised manuscript.

Further, we addressed the journal requirements on style requirements, inclusion of registration number for the clinical trial and data availability statement. We updated our data availability statement as follows:

Legal restrictions in Switzerland prohibit public release of original patient data without consent. The authors' fully anonymized data is exempt from these legal restrictions. However, the data could be deanonymized by individuals or organizations, such as health insurers, which have overlapping data (e.g. patient year of birth and consultation dates). Data access queries can be addressed to Rahel Meier (<rahel.meier@usz.ch>) after clearance by the local ethics committee or to the Kantonale Ethikkommission Zurich (Local Ethics Committee of the Canton of Zurich) (<Info.KEK@kek.zh.ch>).

Unfortunately, we are not allowed to make our data publicly available, even after removing certain types of information. With the addition of further publications, the entire database would gradually become accessible.

We hope our revision to be satisfactory and sufficient for the manuscript to be accepted for publication in Plos One.

We look forward to receiving your response.

Kind regards on behalf of all authors,

Rahel Meier
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Click here for additional data file.
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Quality performance and associated factors in Swiss diabetes care -- a cross-sectional study

PLOS ONE

Dear Ms Meier,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 11 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Valérie Pittet, PhD

Academic Editor

PLOS ONE

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Here is a list of specific comments. Note: line and page numbering in reviews and comments is based on ruler applied in Editorial Manager-generated PDF.

1\. Page 7, lines 134--136: The cumulative QI performance ranged from 0 to 6. Please clarify the use of the hierarchical multivariable "binomial" regression model for an ordinal outcome. Did you mean a hierarchical multivariable ordinal logistic regression model where the odds would be interpreted as the odds of having more QI performance?

Reviewer \#2: Thank you for making these changes. I only have some small further suggestions regarding the manuscript. As an aside, please note when responding to reviewer comments in future it is very helpful to firstly, provide some detail on the nature of the revision made and secondly, to indicate the line numbers where the revisions have been made. This makes it much easier (and quicker) for the reviewer to assess the changes.

In my previous review I suggested clarifying what you mean by "Structural data on participating GP are collected at individual project entry." (line 75). Thank you for adding further detail to explain that this was done manually. However, I feel you should tell the reader who collected this information - I presume the research team?

There are still some typos in places throughout the manuscript so would advise careful proofreading before submission e.g. However, one can indirectly conclude from medication prescriptions that, the majority of included patients were patients with type 2 diabetes.

In the previous review I suggested rephrasing this sentence (line 188) as it as unclear what was meant. I suggest further rewording as this could be clearer and have included amendment:

"Number of years since diabetes diagnosis was much shorter in our study, which is explained by the fact limited data were available from before GPs participated in the FIRE project."

In my previous review I noted that the Stone et al study (line 195) was missing a reference and that I thought this sentence was meant to be connected to the previous line. Thank you for adding the reference to the study. It is always helpful for the reader to have the reference cited a that place in the text even if the article was introduced earlier in the manuscript, particularly as you are using Vancouver referencing style. You did not address the second part of this comment. The sentence begins with 'whereas' and so hence my question about whether it should be connected to the preceding sentence. For example, I suggest it would read as:

\"The proportions of patients fulfilling the process and outcome indicators for BP and HbA1c were highly comparable to the methodological similar study of van Doorn-Klomberg et al. 2015 \[13\], whereas the European cross-sectional study by Stone et al. 2013 \[27\] reported process indicators above 90%.\"

Thank you for amending line 224. However, this sentence is still unclear. I think it should read as follows such that you clarify the direction of the effect:

\"This finding is not completely in line with Lustman et al. 2016 \[37\], reporting a positive effect of continuity of care on the major clinical outcomes\"

Reviewer \#3: The authors have adequately addressed all points I raised. The revised manuscript has improved, is well written and an interesting piece of research. I have no further comments.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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1.1 Page 7, lines 134--136: The cumulative QI performance ranged from 0 to 6. Please clarify the use of the hierarchical multivariable "binomial" regression model for an ordinal outcome. Did you mean a hierarchical multivariable ordinal logistic regression model where the odds would be interpreted as the odds of having more QI performance?

Thank you for your comment. By binomial regression, we meant that the dependent variable was defined as the -- binomially distributed - cumulative QI performance: (cumulative QI performance, 6- cumulative QI performance), where the odds would be interpreted as the odds of satisfying an individual QI. We added more details to the manuscript (lines 139 -- 140 in the manuscript with tracked changes) and hope that it is now better understandable what we meant.

2.1 In my previous review I suggested clarifying what you mean by "Structural data on participating GP are collected at individual project entry." (line 75). Thank you for adding further detail to explain that this was done manually. However, I feel you should tell the reader who collected this information - I presume the research team?

Thank you for your comment. We clarified further, as you suggested, that the GPs self-reported the structural information to our study nurse (lines 78 - 80 in the manuscript with tracked changes)

2.2 There are still some typos in places throughout the manuscript so would advise careful proofreading before submission e.g. However, one can indirectly conclude from medication prescriptions that, the majority of included patients were patients with type 2 diabetes.

Thank you for pointing out this specific sentence. We made corrections to this sentence and carefully proofread the whole manuscript and made some minor changes throughout.

2.3 In the previous review I suggested rephrasing this sentence (line 188) as it as unclear what was meant. I suggest further rewording as this could be clearer and have included amendment:

"Number of years since diabetes diagnosis was much shorter in our study, which is explained by the fact limited data were available from before GPs participated in the FIRE project."

Thank you for your suggestion and for clarifying its meaning. We changed the sentence as you suggested (lines 217 -219 in the manuscript with tracked changes).

2.4 In my previous review I noted that the Stone et al study (line 195) was missing a reference and that I thought this sentence was meant to be connected to the previous line. Thank you for adding the reference to the study. It is always helpful for the reader to have the reference cited a that place in the text even if the article was introduced earlier in the manuscript, particularly as you are using Vancouver referencing style. You did not address the second part of this comment. The sentence begins with 'whereas' and so hence my question about whether it should be connected to the preceding sentence. For example, I suggest it would read as:

\"The proportions of patients fulfilling the process and outcome indicators for BP and HbA1c were highly comparable to the methodological similar study of van Doorn-Klomberg et al. 2015 \[13\], whereas the European cross-sectional study by Stone et al. 2013 \[27\] reported process indicators above 90%.\"

Thank you for your suggestion. We adapted the sentence as you suggested (line 224 in the manuscript with tracked changes).

2.5 Thank you for amending line 224. However, this sentence is still unclear. I think it should read as follows such that you clarify the direction of the effect:

\"This finding is not completely in line with Lustman et al. 2016 \[37\], reporting a positive effect of continuity of care on the major clinical outcomes

Thank you for your comment. We changed the sentence as you suggested and clarified the direction of the effect (line 253 in the manuscript with tracked changes).
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Quality performance and associated factors in Swiss diabetes care -- a cross-sectional study

PONE-D-19-32658R2

Dear Dr. Meier,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Valérie Pittet, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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PONE-D-19-32658R2

Quality performance and associated factors in Swiss diabetes care -- a cross-sectional study

Dear Dr. Meier:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

PD Dr. Valérie Pittet

Academic Editor

PLOS ONE
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